Clinico-epidemiological Profile, Comorbidities, Prevailing Practices in the Management of Hyperuricemia and Patient Outcomes with Various Urate Lowering Therapies: Capital Registry Data
Journal of Clinical Nephrology · 22.06.2026 · 10 (6) · 50-57
DOI: 10.29328/journal.jcn.1001176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Nephrology, online erschienen am 22.06.2026. Verfasst von Sanjiv Jasuja und 9 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The absence of standardized protocols for managing hyperuricemia (HU) in chronic kidney disease (CKD) patients in India highlights the need to examine current practices. This registry assessed clinico-epidemiological data, treatment strategies, and outcomes with urate-lowering drugs (ULD) in CKD stages 2 to 4 across India.
Methods
This observational registry included 251 CKD patients with HU across five centers over 12 months. Primary endpoints were demographic data, CKD stages, and comorbidities. Secondary endpoints included percentages of patients on treatment (ULD, lifestyle modification [LSM], or both) and their impact on kidney function tests (KFTs). Comparisons were made between therapies (LSM vs. LSM+ULD) and comorbidity subgroups.
Results
Among 251 CKD patients, 48.6% had stage 4 CKD, and 58.2% had SUA levels 6-8 mg/dL (mean age: 46.77 years; 69.7% men). Hypertension (90%) was most common, followed by diabetes (41%). At 12 months, mean SUA reduction was significant (-2.36 ± 1.85). Similar reductions occurred in patients with comorbidities: diabetes (-2.52 ± 1.83), hypertension (-2.39 ± 1.86), diabetes + hypertension (-2.51 ± 1.84) and others (-2.83 ± 2.06). Reduction was greater in patients treated with LSM+ULD (-2.89 ± 1.64) compared to LSM alone (-0.62 ± 1.69). A significant eGFR increase was noted overall, with ULD+LSM group showing higher eGFR (15.21 ± 25.61) than LSM-only group (-1.26 ± 10.41). Seventeen adverse events (AEs) and three serious AEs were reported, all except one were unrelated.
Conclusion
The study highlights younger onset, male predominance, and higher ULD use in Indian CKD patients with hyperuricemia, supporting potential benefit of ULD+LSM in the management of CKD.
Zitieren
APA
Jasuja, S., Hiremath, S., Nagaraju, S. P., Balwani, M., Pasari, A., Bhojaraja, M. V., Sharma, Y., Sholapuri, D., Acharya, S., & Rane, R. (2026). Clinico-epidemiological Profile, Comorbidities, Prevailing Practices in the Management of Hyperuricemia and Patient Outcomes with Various Urate Lowering Therapies: Capital Registry Data. Journal of Clinical Nephrology, 10(6), 50-57. https://doi.org/10.29328/journal.jcn.1001176
Vancouver
Jasuja S, Hiremath S, Nagaraju SP, Balwani M, Pasari A, Bhojaraja MV, et al. Clinico-epidemiological Profile, Comorbidities, Prevailing Practices in the Management of Hyperuricemia and Patient Outcomes with Various Urate Lowering Therapies: Capital Registry Data. Journal of Clinical Nephrology. 2026;10(6):50-57. doi:10.29328/journal.jcn.1001176
BibTeX
@article{Jasuja2026,
author = {Jasuja, Sanjiv and Hiremath, Sanjeev and Nagaraju, Shankar Prasad and Balwani, Manish and Pasari, Amit and Bhojaraja, Mohan V and Sharma, Yogesh and Sholapuri, Deepa and Acharya, Shivani and Rane, Rhutuja},
title = {Clinico-epidemiological Profile, Comorbidities, Prevailing Practices in the Management of Hyperuricemia and Patient Outcomes with Various Urate Lowering Therapies: Capital Registry Data},
journal = {Journal of Clinical Nephrology},
year = {2026},
volume = {10},
number = {6},
pages = {50--57},
doi = {10.29328/journal.jcn.1001176}
}
EUVIMED